Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

Summary

Company, the leading business intelligence provider, has released its latest research “Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma”. The report provides in-depth analysis of drivers and barriers that impact the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.

The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary Tract Infections (UTI), pneumonia, Bloodstream Infections (BSI) and Surgical Site Infections (SSI). The total market of HABI is dependent on the major infections which are mainly caused by multi-drug resistant bacteria. Increasing human resistance to anti-bacterials leads to a need for advanced therapies to treat bacterial infections. Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low Return on Investment (RoI). The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen their antibacterial pipeline portfolio.

The HABI market will show decline in the forecast period. The market is forecast to decline at a negative CAGR of 3.4% in the forecast period 2010–2017. Decline in the HABI market will be due to two main reasons. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on CDC data, 20% to 30% of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare setup.

Scope

- Annualized market data for the HABI market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, J&J, Cubist and other niche companies like Trius Therapeutics and Tetraphase Pharmaceuticals.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of leading companies and niche companies which are helpful in extending pipeline portfolio.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
 

1.1 List of Tables 5
1.2 List of Figures 7
2 Global Hospital Acquired Bacterial Infections Market - Introduction 9
2.1 GBI Research Report Guidance 9
3 Global Hospital Acquired Bacterial Infections Market - Market Overview 10
3.1 Introduction 10
3.2 Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market 11
3.2.1 Sales Value 11
3.2.2 Annual Cost of Therapy 13
3.2.3 Treatment Usage Patterns 14
3.3 Hospital Acquired Bacterial Infections Market Drivers 15
3.3.1 Increase in Antibacterial Resistance due to Their Frequent Usage 15
3.3.2 Threat from Emergence of Superbugs 15
3.4 Hospital Acquired Bacterial Infections Market Restraints 16
3.4.1 Increased Penetration of Generics Pose as a Threat for Primary Manufacturers 16
3.4.2 Increased Anti-bacterial Surveillance in Hospitals 16
4 Global Hospital Acquired Bacterial Infections Market - Therapeutic Landscape 17
4.1 Hospital Acquired Urinary Tract Infections (UTI) Market 17
4.1.1 Introduction 17
4.1.2 Sales Value 17
4.1.3 Annual Cost of Therapy 19
4.1.4 Treatment Flow Algorithm 20
4.1.5 Treatment Usage Patterns 21
4.1.6 Market Share by Geography 23
4.2 Hospital Acquired Bacterial Pneumonia (HABP) Market 24
4.2.1 Introduction 24
4.2.2 Sales Value 25
4.2.3 Annual Cost of Therapy 26
4.2.4 Treatment Flow Algorithm 27
4.2.5 Treatment Usage Patterns 28
4.2.6 Market Share by Geography 30
4.3 Hospital Acquired Bacterial Surgical Site Infections Market 31
4.3.1 Introduction 31
4.3.2 Sales Value 31
4.3.3 Annual Cost of Therapy 33
4.3.4 Treatment Flow Algorithm 34
4.3.5 Treatment Usage Patterns 35
4.3.6 Market Share by Geography 37
4.4 Hospital Acquired Bacterial Blood Stream Infections (BSI) Market 39
4.4.1 Introduction 39
4.4.2 Sales Value 39
4.4.3 Annual Cost of Therapy 40
4.4.4 Treatment Flow Algorithm 41
4.4.5 Treatment Usage Patterns 42
4.4.6 Market Share by Geography 44
5 Global Hospital Acquired Bacterial Infections Market - Geographical Landscape 46
5.1 Geographical Break-up 46
5.2 The US 48
5.2.1 Sales Value 48
5.2.2 Annual Cost of Therapy 49
5.2.3 Treatment Usage Patterns 50
5.3 Top Five Countries in Europe 52
5.3.1 Sales Value 52
5.3.2 Country Segmentation 53
5.3.3 Annual Cost of Therapy 54
5.3.4 Treatment Usage Patterns 55
5.4 Japan 57
5.4.1 Sales Value 57
5.4.2 Annual Cost of Therapy 58
5.4.3 Treatment Usage Patterns 59
6 Global Hospital Acquired Bacterial Infections - Pipeline Analysis 61
6.1 Pipeline Drugs by Phase of Development 61
6.2 Research and Development Pipeline 61
6.2.1 Phase III Pipeline Molecules 61
6.2.2 Phase II Pipeline Molecules 62
6.2.3 Phase I, Pre-Clinical and Discovery Phase Molecules 63
6.3 Profiles of Key Late Stage Drugs 64
6.3.1 Oritavancin 64
6.3.2 Torezolid 65
6.3.3 Ceftobiprole Medocaril 66
6.3.4 Omadacycline/ PTK 0796 66
6.3.5 Oritavancin 67
7 Global Hospital Acquired Bacterial Infections Market - Competitive Landscape 68
7.1 Competitive Profiling 68
7.1.1 Johnson & Johnson (J&J) 68
7.1.2 Pfizer 69
7.1.3 Cubist Pharmaceuticals 70
7.1.4 Bayer 71
7.1.5 Trius Therapeutics 72
7.1.6 Tetraphase Pharmaceuticals Inc. 72
8 Global Hospital Acquired Bacterial Infections Market - Strategic Consolidations 73
8.1 Overview 73
8.2 M&A Deals by Geography 73
8.3 M&A Deals by Value 74
8.4 M&A Deals by Deal Type 75
8.4.1 Merck Completes Acquisition Of Inspire Pharmaceuticals 75
8.4.2 SciClone Pharmaceuticals Acquires NovaMed Pharmaceuticals 76
8.4.3 AstraZeneca Completed the Acquisition of Novexel SA in March 2010 76
8.5 R&D Licensing Agreements 76
8.5.1 Major Licensing Agreements 77
9 Global Hospital Acquired Bacterial Infections Market - Appendix 79
9.1 Market Definitions 79
9.2 Abbreviations 79
9.3 Research Methodology 80
9.3.1 Coverage 80
9.3.2 Secondary Research 80
9.3.3 Primary Research 81
9.3.4 Therapeutic Landscape 81
9.3.5 Market Size by Geography 84
9.3.6 Geographical Landscape 85
9.3.7 Pipeline Analysis 85
9.3.8 Competitive Landscape 85
9.3.9 Expert Panel Validation 85
9.4 Contact Us 85
9.5 Disclaimer 85
9.6 Sources 86

1.1 List of Tables
Table 1: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2010 11
Table 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2010-2017 11
Table 3: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 13
Table 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 13
Table 5: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2002-2010 14
Table 6: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2010-2017 15
Table 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2010 18
Table 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2010-2017 18
Table 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 19
Table 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 20
Table 11: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2010 21
Table 12: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2010-2017 22
Table 13: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2010 23
Table 14: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2010-2017 24
Table 15: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2010 25
Table 16: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2010-2017 25
Table 17: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2010 26
Table 18: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2010-2017 26
Table 19: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2010 28
Table 20: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2010-2017 29
Table 21: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2002-2010 30
Table 22: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2010-2017 31
Table 23: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2010 32
Table 24: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2010-2017 32
Table 25: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 33
Table 26: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 33
Table 27: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010 35
Table 28: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017 36
Table 29: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2010 37
Table 30: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2010-2017 38
Table 31: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2010 39
Table 32: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2010-2017 40
Table 33: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 40
Table 34: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 41
Table 35: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010 42
Table 36: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017 43
Table 37: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2010 44
Table 38: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2010-2017 45
Table 39: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2010 46
Table 40: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2010-2017 47
Table 41: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2010 48
Table 42: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2010-2017 48
Table 43: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2010 49
Table 44: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2010-2017 49
Table 45: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2010 50
Table 46: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2010-2017 51
Table 47: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010 52
Table 48: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017 52
Table 49: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010 53
Table 50: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017 53
Table 51: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 54
Table 52: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 54
Table 53: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2002-2010 55
Table 54: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2010-2017 55
Table 55: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2010 57
Table 56: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2010-2017 57
Table 57: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2010 58
Table 58: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2010-2017 58
Table 59: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2010 59
Table 60: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2010-2017 60
Table 61: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase III, 2011 61
Table 62: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase II, 2011 62
Table 63: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase I, Discovery, Pre-Clinical, 2011 63
Table 64: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals, 2011 75

1.2 List of Figures
Figure 1: Hospital Acquired Bacterial Infections Market, Global, Drivers and Restraints, 2011 10
Figure 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2017 11
Figure 3: Hospital Acquired Bacterial Infections Market, Global, Revenue Segmentation, 2010, 2017 12
Figure 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 13
Figure 5: Hospital Acquired Bacterial Infections Market, Global, Therapeutic Usage Patterns (million), 2002-2017 14
Figure 6: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2017 18
Figure 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 19
Figure 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Flow Algorithm 20
Figure 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 21
Figure 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2017 23
Figure 11: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2017 25
Figure 12: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2017 26
Figure 13: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Flow Algorithm 27
Figure 14: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2017 28
Figure 15: Hospital Acquired Bacterial Pneumonia Market, Global, Market Geographical Segmentation ($m), 2002-2017 30
Figure 16: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2017 32
Figure 17: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 33
Figure 18: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Flow Algorithm 34
Figure 19: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 35
Figure 20: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2017 37
Figure 21: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2017 39
Figure 22: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 40
Figure 23: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Flow Algorithm 41
Figure 24: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 42
Figure 25: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2017 44
Figure 26: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2017 46
Figure 27: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2017 48
Figure 28: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2017 49
Figure 29: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2017 50
Figure 30: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017 52
Figure 31: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017 53
Figure 32: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 54
Figure 33: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Patterns (thousand), 2002-2017 55
Figure 34: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2017 57
Figure 35: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2017 58
Figure 36: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2017 59
Figure 37: Hospital Acquired Bacterial Infections, Global, Pipeline by Phase (%), 2010 61
Figure 38: Hospital Acquired Bacterial Infections Market, Global, SWOT - Johnson & Johnson, 2010 69
Figure 39: Hospital Acquired Bacterial Infections Market, Global, SWOT - Pfizer, 2010 70
Figure 40: Hospital Acquired Bacterial Infections Market, Global, SWOT - Cubist, 2010 71
Figure 41: Hospital Acquired Bacterial Infections Market, Global, SWOT - Bayer, 2010 72
Figure 42: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Geography (%), 2004-2011 73
Figure 43: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Value (%), 2004-2011 74
Figure 44: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals by Deal Type (%), 2004-2011 75
Figure 45: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Geography (%), 2004-2011 76
Figure 46: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Value (%), 2004-2011 77
Figure 47: GBI Research Market Forecasting Model 84

Companies Mentioned

 Johnson & Johnson (J&J)
Pfizer
Cubist Pharmaceuticals
Bayer
Trius Therapeutics
Tetraphase Pharmaceuticals Inc.